drugset / Trial / NCT07164183

Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

NCT07164183

Phase 3 Recruiting 290 enrolled Alcea
RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective open-label randomized parallel groups study to compare efficacy and safety of Indinol Forto® 200 mg capsules and Visanne 2 mg tablets in treatment of endometriosis. This is phase 3 study, based on hypothesis of non-inferiority.

Timeline

Start
2025-09-11
Primary completion
2026-10
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dienogest Small molecule 2 mg Oral
Subject Indole-3-carbinol Small molecule 200 mg Oral

Indications